Zomedica Corp. Income Statement
ZOMDF|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Zomedica Corp. reported $32M in revenue and $82M in net loss for FY2025. Revenue has grown at a 66.8% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $32.0M | $27.3M | $25.2M | $18.9M | $4.1M | $0 |
| Cost of Revenue | $10.4M | $8.2M | $7.9M | $5.5M | $1.1M | $0 |
| Gross Profit | $21.7M | $19.1M | $17.3M | $13.5M | $3.1M | $0 |
| SG&A Expense | $24.5M | $29.7M | $29.0M | $22.9M | $22.8M | $8.7M |
| R&D Expense | $7.2M | $7.3M | $5.7M | $2.6M | $1.7M | $8.0M |
| Operating Income | -$84.4M | -$51.1M | -$43.3M | -$21.9M | -$21.4M | -$16.8M |
| Interest Expense | - | - | $175.0K | $1.0K | $6.0K | $732 |
| Income Tax | -$278.0K | -$557.0K | -$1.3M | -$2.4M | -$2.3M | $0 |
| Net Income | -$81.9M | -$47.0M | -$34.5M | -$17.0M | -$18.4M | -$16.9M |
| EPS (Basic) | -$0.08 | -$0.05 | -$0.04 | -$0.02 | - | - |
| EPS (Diluted) | -$0.08 | -$0.05 | -$0.04 | -$0.02 | -$0.05 | -$0.05 |
| Shares Outstanding | 979.9M | 979.9M | 979.9M | 979.9M | 979.9M | 642.0M |
| Gross Margin | 67.7% | 70.0% | 68.8% | 71.2% | 73.9% | - |
| Operating Margin | -263.4% | -187.1% | -171.8% | -115.8% | -517.1% | - |
| Profit Margin | -255.6% | -172.2% | -137.1% | -89.9% | -444.8% | - |